(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are SAS AB, NYXOAH, and DEEZER.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| SAS AB (SASNO.OL) | 0.30 | 28.76% | 2023-04-17 08:33:06 |
| NYXOAH (NYXH.BR) | 9.22 | 15.25% | 2023-04-17 11:16:00 |
| DEEZER (DEEZR.PA) | 1.41 | 13.71% | 2023-04-17 11:47:37 |
| MYHOTELMATCH (MHM.PA) | 0.04 | 11.25% | 2023-04-17 11:00:34 |
| SOC FRANC CASINOS (SFCA.PA) | 1.98 | 10.61% | 2023-04-17 11:03:22 |
| MKB Nedsense (NEDSE.AS) | 0.10 | 8.42% | 2023-04-17 08:03:11 |
| ORPEA (ORP.PA) | 2.91 | 7.74% | 2023-04-17 11:01:11 |
| ABIVAX (ABVX.PA) | 10.74 | 7.51% | 2023-04-17 11:35:24 |
| AFFLUENT MEDICAL (AFME.PA) | 1.29 | 7.08% | 2023-04-17 11:35:56 |
| CADELER (CADLR.OL) | 44.28 | 6.96% | 2023-04-17 11:21:08 |
The three biggest losers today are FINATIS, REDITUS,SGPS, and PROACTIS SA.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| FINATIS (FNTS.PA) | 4.16 | -33.44% | 2023-04-17 08:49:04 |
| REDITUS,SGPS (RED.LS) | 0.03 | -25% | 2023-04-17 11:19:18 |
| PROACTIS SA (PROAC.PA) | 0.10 | -14.6% | 2023-04-17 11:01:54 |
| ADC SIIC (ALDV.PA) | 0.07 | -13.33% | 2023-04-17 11:35:41 |
| NEW SOURCES ENERGY (NSE.AS) | 0.04 | -12.5% | 2023-04-17 11:03:34 |
| HOTELS DE PARIS (HDP.PA) | 1.19 | -7.03% | 2023-04-17 08:50:21 |
| CELYAD ONCOLOGY (CYAD.BR) | 0.66 | -6.48% | 2023-04-17 11:06:18 |
| PETROLIA (PSE.OL) | 3.93 | -6.21% | 2023-04-17 11:32:29 |
| AXA NV23 (CSNV.PA) | 25.81 | -6.15% | 2023-04-17 11:45:02 |
| MAAT PHARMA (MAAT.PA) | 9.40 | -4.86% | 2023-04-17 08:51:38 |
Winners today
1. SAS AB (SASNO.OL)
28.76% Price Change
SAS AB (publ), together with its subsidiaries, provides passenger flight transportation services in the Nordic and international route network. The company also offers air cargo services, in-flight sales, ground handling, and technical maintenance services, as well as travel-related loyalty programs. It operates a fleet of 135 aircraft, including 12 long-haul aircraft, 95 short-haul aircraft, and 28 aircraft flown by regional production partners. The company was founded in 1946 and is headquartered in Stockholm, Sweden. On July 5, 2022, SAS AB (publ), along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Oslo Børs Benchmark Index_GI ended the session with SAS AB rising 28.76% to €0.30 on Monday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.22% to €1,227.25, after four consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, SAS AB has a trailing twelve months EPS of kr-0.94.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1151.97%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SAS AB’s stock is considered to be overbought (>=80).
Moving Average
SAS AB’s value is way under its 50-day moving average of kr0.42 and way below its 200-day moving average of kr0.52.
More news about SAS AB.
2. NYXOAH (NYXH.BR)
15.25% Price Change
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with NYXOAH jumping 15.25% to €9.22 on Monday, after five sequential sessions in a row of gains. BEL 20 rose 0.3% to €3,849.52, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, NYXOAH has a trailing twelve months EPS of €-1.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NYXOAH’s EBITDA is -3.76.
More news about NYXOAH.
3. DEEZER (DEEZR.PA)
13.71% Price Change
Deezer S.A. provides music streaming services worldwide. The company streams songs, audio books, and radio channels. It offers its music steaming services through website, Deezer.com and a mobile application; and operates in approximately 180 countries. The company was founded in 2006 and is based in Paris, France.
CAC 40 ended the session with DEEZER jumping 13.71% to €1.41 on Monday while CAC 40 dropped 0.28% to €7,498.18.
Earnings Per Share
As for profitability, DEEZER has a trailing twelve months EPS of €4.33.
PE Ratio
DEEZER has a trailing twelve months price to earnings ratio of 0.33. Meaning, the purchaser of the share is investing €0.33 for every euro of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DEEZER’s stock is considered to be overbought (>=80).
Volatility
DEEZER’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.20%, a negative 0.67%, and a positive 2.61%.
DEEZER’s highest amplitude of average volatility was 1.36% (last week), 1.21% (last month), and 2.61% (last quarter).
Volume
Today’s last reported volume for DEEZER is 25075 which is 73.45% above its average volume of 14456.
Yearly Top and Bottom Value
DEEZER’s stock is valued at €1.41 at 22:40 EST, way below its 52-week high of €8.50 and higher than its 52-week low of €1.33.
More news about DEEZER.
4. MYHOTELMATCH (MHM.PA)
11.25% Price Change
MyHotelMatch S.A. engages in the development and exploitation of an online hotel reservation platform based on Artificial Intelligence (AI). It operates as an online travel agency based on the principle of online dating. The company, through its platform, connect a traveler and hotels with online hotel services whose profiles match. The company is based in Biot, France.
CAC 40 ended the session with MYHOTELMATCH jumping 11.25% to €0.04 on Monday, following the last session’s upward trend. CAC 40 slid 0.28% to €7,498.18, after five consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, MYHOTELMATCH has a trailing twelve months EPS of €-0.05.
Volatility
MYHOTELMATCH’s last week, last month’s, and last quarter’s current intraday variation average was 3.19%, 2.48%, and 7.13%.
MYHOTELMATCH’s highest amplitude of average volatility was 7.15% (last week), 6.53% (last month), and 7.13% (last quarter).
Yearly Top and Bottom Value
MYHOTELMATCH’s stock is valued at €0.04 at 22:40 EST, above its 52-week high of €0.04.
Moving Average
MYHOTELMATCH’s value is way above its 50-day moving average of €0.03 and way higher than its 200-day moving average of €0.02.
More news about MYHOTELMATCH.
5. SOC FRANC CASINOS (SFCA.PA)
10.61% Price Change
Société Française de Casinos Société Anonyme operates casinos in France. The company is also involved in the hotel and restaurant activities. The company is based in Paris, France.
CAC 40 ended the session with SOC FRANC CASINOS rising 10.61% to €1.98 on Monday, following the last session’s upward trend. CAC 40 dropped 0.28% to €7,498.18, after five consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, SOC FRANC CASINOS has a trailing twelve months EPS of €0.34.
PE Ratio
SOC FRANC CASINOS has a trailing twelve months price to earnings ratio of 5.82. Meaning, the purchaser of the share is investing €5.82 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.61%.
Volume
Today’s last reported volume for SOC FRANC CASINOS is 204 which is 12.08% above its average volume of 182.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SOC FRANC CASINOS’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.4%, now sitting on 13.26M for the twelve trailing months.
Yearly Top and Bottom Value
SOC FRANC CASINOS’s stock is valued at €1.98 at 22:40 EST, under its 52-week high of €2.02 and way higher than its 52-week low of €1.36.
More news about SOC FRANC CASINOS.
6. MKB Nedsense (NEDSE.AS)
8.42% Price Change
MKB Nedsense N.V. engages in the finance and lending of money to natural persons and legal entities. It also provides guarantees and/or other securities towards third parties for its obligations and/or for obligations for companies in the investment portfolio. The company was formerly known as Nedsense Enterprises N.V. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands.
AEX-Index ended the session with MKB Nedsense jumping 8.42% to €0.10 on Monday while AEX-Index fell 0.38% to €758.50.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MKB Nedsense’s stock is considered to be overbought (>=80).
Volatility
MKB Nedsense’s last week, last month’s, and last quarter’s current intraday variation average was a negative 8.70%, a negative 2.35%, and a positive 4.50%.
MKB Nedsense’s highest amplitude of average volatility was 9.93% (last week), 6.29% (last month), and 4.50% (last quarter).
More news about MKB Nedsense.
7. ORPEA (ORP.PA)
7.74% Price Change
ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.
CAC 40 ended the session with ORPEA rising 7.74% to €2.91 on Monday while CAC 40 slid 0.28% to €7,498.18.
Earnings Per Share
As for profitability, ORPEA has a trailing twelve months EPS of €-6.41.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.36%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 4.52B for the twelve trailing months.
Volume
Today’s last reported volume for ORPEA is 3761240 which is 51.32% above its average volume of 2485510.
Sales Growth
ORPEA’s sales growth is 8.9% for the ongoing quarter and 8.9% for the next.
More news about ORPEA.
8. ABIVAX (ABVX.PA)
7.51% Price Change
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
CAC 40 ended the session with ABIVAX jumping 7.51% to €10.74 on Monday while CAC 40 dropped 0.28% to €7,498.18.
Earnings Per Share
As for profitability, ABIVAX has a trailing twelve months EPS of €-2.57.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1286.47%.
Yearly Top and Bottom Value
ABIVAX’s stock is valued at €10.74 at 22:40 EST, way under its 52-week high of €25.50 and way above its 52-week low of €5.60.
Volatility
ABIVAX’s last week, last month’s, and last quarter’s current intraday variation average was 2.33%, 3.46%, and 2.50%.
ABIVAX’s highest amplitude of average volatility was 4.23% (last week), 4.38% (last month), and 2.50% (last quarter).
More news about ABIVAX.
9. AFFLUENT MEDICAL (AFME.PA)
7.08% Price Change
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.
CAC 40 ended the session with AFFLUENT MEDICAL jumping 7.08% to €1.29 on Monday while CAC 40 slid 0.28% to €7,498.18.
Earnings Per Share
As for profitability, AFFLUENT MEDICAL has a trailing twelve months EPS of €-0.78.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.51%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.3%, now sitting on 1.56M for the twelve trailing months.
Moving Average
AFFLUENT MEDICAL’s worth is way below its 50-day moving average of €1.56 and way under its 200-day moving average of €2.29.
Volatility
AFFLUENT MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.08%, a negative 0.57%, and a positive 2.90%.
AFFLUENT MEDICAL’s highest amplitude of average volatility was 3.06% (last week), 2.39% (last month), and 2.90% (last quarter).
More news about AFFLUENT MEDICAL.
10. CADELER (CADLR.OL)
6.96% Price Change
Cadeler A/S operates as an offshore wind farm transportation and installation contractor in Denmark. The company also provides wind farm maintenance, operations, construction, decommissioning, and other tasks within the offshore industry, as well as operates marine and engineering. It owns and operates two offshore jack-up windfarm installation vessels. The company was formerly known as Swire Blue Ocean A/S and changed its name to Cadeler A/S in October 2020. Cadeler A/S was incorporated in 2008 and is headquartered in Copenhagen, Denmark.
Oslo Børs Benchmark Index_GI ended the session with CADELER jumping 6.96% to €44.28 on Monday, after four consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.22% to €1,227.25, after four sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, CADELER has a trailing twelve months EPS of kr2.48.
PE Ratio
CADELER has a trailing twelve months price to earnings ratio of 17.85. Meaning, the purchaser of the share is investing kr17.85 for every norwegian krone of annual earnings.
Volume
Today’s last reported volume for CADELER is 184714 which is 8.55% above its average volume of 170150.
More news about CADELER.
Losers Today
1. FINATIS (FNTS.PA)
-33.44% Price Change
Finatis Société Anonyme operates in the food distribution business in France and Latin America. It operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. The company also distributes sports equipment under the Go Sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. The company was incorporated in 1971 and is headquartered in Paris, France. Finatis Société Anonyme is a subsidiary of Euris SAS.
CAC 40 ended the session with FINATIS sliding 33.44% to €4.16 on Monday, after five sequential sessions in a row of losses. CAC 40 dropped 0.28% to €7,498.18, after five successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, FINATIS has a trailing twelve months EPS of €-22.97.
Volume
Today’s last reported volume for FINATIS is 120 which is 55.55% below its average volume of 270.
More news about FINATIS.
2. REDITUS,SGPS (RED.LS)
-25% Price Change
Reditus, Sociedade Gestora de Participações Sociais, S.A., through its subsidiaries, provides business process outsourcing, IT outsourcing, and IT consulting services in Portugal and internationally. The company offers client services, including client, financial, human resource, doc, and facilities management, as well as other business process services; and IT infrastructure services and solutions in the areas of advisory, design, installation, and maintenance of systems and solutions, storage, network, and security. It also provides specialized outsourcing services in the areas of application development and maintenance, DBs and system administration, business intelligence and applications, telecom engineering and networks, and support and helpdesk; and information security services and solutions, as well as security managed services. In addition, the company offers enterprise content management services, solutions, and products for deployment of projects in scanning, document management, and workflow in multi-channel topologies; lean management services and solutions in practical application of diagnostic methodologies; and management and IT consulting services and solutions. Further, it is involved in the development, management, and maintenance of software applications and analytical solutions; and provision of cooperation and development services and solutions in the areas of corporate procurement, project management, and economic and social development, as well as training and personal development services. The company serves public, health, telecom, media, utilities, financial services, consumer, retail, and transportation sectors. The company was founded in 1966 and is headquartered in Lisbon, Portugal.
PSI ended the session with REDITUS,SGPS falling 25% to €0.03 on Monday while PSI jumped 0.64% to €6,192.79.
Earnings Per Share
As for profitability, REDITUS,SGPS has a trailing twelve months EPS of €-0.1.
More news about REDITUS,SGPS.
3. PROACTIS SA (PROAC.PA)
-14.6% Price Change
Proactis SA provides source-to-pay software solution. It operates software platform that will give control over business spend. It also offers procurement solutions that provide purchasing professionals with the tools they need for purchasing process for routine goods and services, capital goods, and major projects. In addition, it offers invoice capture services, system administration, supplier onboarding, and tail spent management services. Further, Its solutions integrate with various ERP or financial systems. The company was formerly known as HUBWOO and changed its name to Proactis SA in January 2019. The company is based in Suresnes, France. Proactis SA operates as a subsidiary of Proactis Euro Hedgeco Limited.
CAC 40 ended the session with PROACTIS SA sliding 14.6% to €0.10 on Monday while CAC 40 slid 0.28% to €7,498.18.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.69%.
Volatility
PROACTIS SA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.29%, a negative 1.43%, and a positive 6.50%.
PROACTIS SA’s highest amplitude of average volatility was 4.29% (last week), 5.62% (last month), and 6.50% (last quarter).
More news about PROACTIS SA.
4. ADC SIIC (ALDV.PA)
-13.33% Price Change
Alliance Developpement Capital SIIC (ADC SIIC) is a publicly owned real estate investment firm. The firm specializes in owning and managing residential real estate properties. It primarily invests in properties in Paris and its suburbs. The firm was formerly known as AD Capital SA. Alliance Developpement Capital is based in Saint-Josse-Ten-Noode, Belgium.
CAC 40 ended the session with ADC SIIC sliding 13.33% to €0.07 on Monday, after three successive sessions in a row of losses. CAC 40 fell 0.28% to €7,498.18, after five successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, ADC SIIC has a trailing twelve months EPS of €-0.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.85%.
Yearly Top and Bottom Value
ADC SIIC’s stock is valued at €0.07 at 22:40 EST, way under its 52-week high of €0.09 and way above its 52-week low of €0.06.
Moving Average
ADC SIIC’s value is higher than its 50-day moving average of €0.07 and below its 200-day moving average of €0.07.
Volume
Today’s last reported volume for ADC SIIC is 540 which is 75.56% below its average volume of 2210.
More news about ADC SIIC.
5. NEW SOURCES ENERGY (NSE.AS)
-12.5% Price Change
New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.
AEX-Index ended the session with NEW SOURCES ENERGY sliding 12.5% to €0.04 on Monday, after four successive sessions in a row of losses. AEX-Index dropped 0.38% to €758.50, after two sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.
Volume
Today’s last reported volume for NEW SOURCES ENERGY is 84776 which is 350.17% above its average volume of 18832.
More news about NEW SOURCES ENERGY.
6. HOTELS DE PARIS (HDP.PA)
-7.03% Price Change
Les Hôtels de Paris SA operates and manages hotels in Paris. As of December 31, 2021, it operated 17 hotels in Paris, 1 hotel in St Tropez, and 1 hotel in Marrakech. The company was incorporated in 1992 and is headquartered in Paris, France.
CAC 40 ended the session with HOTELS DE PARIS falling 7.03% to €1.19 on Monday while CAC 40 fell 0.28% to €7,498.18.
Earnings Per Share
As for profitability, HOTELS DE PARIS has a trailing twelve months EPS of €2.09.
PE Ratio
HOTELS DE PARIS has a trailing twelve months price to earnings ratio of 0.57. Meaning, the purchaser of the share is investing €0.57 for every euro of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HOTELS DE PARIS’s stock is considered to be overbought (>=80).
More news about HOTELS DE PARIS.
7. CELYAD ONCOLOGY (CYAD.BR)
-6.48% Price Change
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
BEL 20 ended the session with CELYAD ONCOLOGY dropping 6.48% to €0.66 on Monday, after four consecutive sessions in a row of losses. BEL 20 jumped 0.3% to €3,849.52, after two successive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.63.
Volatility
CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.37%, a negative 0.35%, and a positive 6.12%.
CELYAD ONCOLOGY’s highest amplitude of average volatility was 3.37% (last week), 3.06% (last month), and 6.12% (last quarter).
More news about CELYAD ONCOLOGY.
8. PETROLIA (PSE.OL)
-6.21% Price Change
Petrolia SE, together with its subsidiaries, operates as a rental equipment company for the oil industry in Norway, rest of Europe, Asia, Australia, and internationally. It operates in two segments, Exploration & Production, and Oil Service. The company engages in the sale and rental of drilling equipment; and rental of land rigs. It rents drilling equipment, such as drill pipes, test strings and tubing, and other equipment, as well as casing, handling, and auxiliary tools. The company also provides equipment inspection and maintenance services. In addition, it offers casing and tubing running, drilling, and make and brake services. It serves oil companies, drilling contractors, and oil service companies. The company was formerly known as Petrolia E&P Holdings SE and changed its name to Petrolia SE in January 2013. Petrolia SE was founded in 1997 and is based in Limassol, Cyprus.
Oslo Børs Benchmark Index_GI ended the session with PETROLIA dropping 6.21% to €3.93 on Monday while Oslo Børs Benchmark Index_GI jumped 0.22% to €1,227.25.
Earnings Per Share
As for profitability, PETROLIA has a trailing twelve months EPS of kr-0.56.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.9%, now sitting on 55.5M for the twelve trailing months.
Yearly Top and Bottom Value
PETROLIA’s stock is valued at kr3.93 at 22:40 EST, way below its 52-week high of kr9.50 and higher than its 52-week low of kr3.90.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PETROLIA’s stock is considered to be oversold (<=20).
More news about PETROLIA.
9. AXA NV23 (CSNV.PA)
-6.15% Price Change
AXA SA, through its subsidiaries, provides insurance, asset management, and banking services worldwide. The company operates through six segments: France, Europe, Asia, AXA XL, International, and Transversal & Central Holdings. It offers life and savings insurance products, such as savings and retirement, other health, and personal protection products. The company also provides property and casualty insurance products, including car, home, and personal or professional liability to individual and business clients; international insurance for large corporate clients in Europe; and marine and aviation insurance services, as well as property and casualty reinsurance products. In addition, it offers asset management services in the areas of various asset classes, including equities, bonds, hedge funds, private equity, and real estate for the group's insurance companies and their clients, and retail and institutional clients. Further, the company provides health, term life, whole life, universal life, endowment, and other investment-based products for personal/individual and commercial/ group customers. AXA SA was founded in 1852 and is headquartered in Paris, France.
CAC 40 ended the session with AXA NV23 falling 6.15% to €25.81 on Monday while CAC 40 fell 0.28% to €7,498.18.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.69%.
More news about AXA NV23.
10. MAAT PHARMA (MAAT.PA)
-4.86% Price Change
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
CAC 40 ended the session with MAAT PHARMA falling 4.86% to €9.40 on Monday, after two successive sessions in a row of losses. CAC 40 dropped 0.28% to €7,498.18, after five consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, MAAT PHARMA has a trailing twelve months EPS of €-1.38.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MAAT PHARMA’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for MAAT PHARMA is 457 which is 56.09% below its average volume of 1041.
Volatility
MAAT PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.30%, a positive 0.62%, and a positive 2.39%.
MAAT PHARMA’s highest amplitude of average volatility was 0.40% (last week), 2.41% (last month), and 2.39% (last quarter).
More news about MAAT PHARMA.
Stay up to date with our winners and losers daily report
